Elevation Oncology Inc (ELEV) - Total Liabilities
Based on the latest financial reports, Elevation Oncology Inc (ELEV) has total liabilities worth $35.49 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Elevation Oncology Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Elevation Oncology Inc's total liabilities have evolved over time, based on quarterly financial data. See ELEV net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Elevation Oncology Inc Competitors by Total Liabilities
The table below lists competitors of Elevation Oncology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Doosan Solus Co Ltd Pref 1P
KO:33637K
|
Korea | ₩1.08 Trillion |
|
Alla Public Company Limited
BK:ALLA
|
Thailand | ฿212.07 Million |
|
BeMetals Corp
V:BMET
|
Canada | CA$12.91 Million |
|
Kumho Electric
KO:001210
|
Korea | ₩20.66 Billion |
|
OD6 Metals Ltd
AU:OD6
|
Australia | AU$1.12 Million |
|
Elspec
TA:ELSPC
|
Israel | ILA23.47 Million |
|
Seko S.A.
WAR:SEK
|
Poland | zł51.52 Million |
|
Ocean Vantage Holdings Bhd
KLSE:0220
|
Malaysia | RM20.33 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Elevation Oncology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Elevation Oncology Inc (ELEV) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 19.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Elevation Oncology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Elevation Oncology Inc (2019–2024)
The table below shows the annual total liabilities of Elevation Oncology Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $35.60 Million | +3.85% |
| 2023-12-31 | $34.28 Million | -24.04% |
| 2022-12-31 | $45.13 Million | +413.00% |
| 2021-12-31 | $8.80 Million | -91.54% |
| 2020-12-31 | $103.99 Million | +1235.41% |
| 2019-12-31 | $7.79 Million | -- |
About Elevation Oncology Inc
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It's lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable link… Read more